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Objectives
We performed an observational study to evaluate the
efficacy of adalimumab treatment of uveitis and arthritis
in patients with juvenile idiopathic arthritis.
Results
23 JIA patients with polyarticular course (initial diagno-
sis: 12 oligo , 2 systemic, 2 psoriatic arthritis, 4 ERA and
3 polyarticular) were treated with adalimumab. Uveitis
was found in 14 patients. (SoJIA: 2/2; OligoJIA 12/12).
The results of the first six months are communicated.
Ocular: During the first six months of adalimumab
treatment no new uveitis episodes occurred. In all
patients visual acuity was impaired during the active
uveitis phase at the start of adalimumab treatment.
Some patients (5/14) recovered sight completely, but in
the others impairment of visual acuity remained. The
anterior chamber cellularity decreased dramatically in
the first 8 weeks. Yet in three patients a low number of
white blood cells was still seen after 24 weeks.
Articular: the number of active joints ranged from 0 to 5
(mean 1,30, median 2) at start, at 3 months mean = 0,70
and median = 1, range 0 - 4 and at six months mean =
0,22, median 0, range 0 - 2. The number of joints with
LOM ranged from 0 – 5 (mean 1,43, median 1) at start,
mean 0,91 after 3 months (median 0, range 0 -5) and
mean 0,39 after 6 months (median 0, range 0 – 4).
Conclusion
Despite the limitations of a relatively small patient
group adalimumab treatment shows to be beneficial in
JIA patients as well on the ocular disease as on the
arthritis. Especially for uveitis we need larger long-
term prospective randomized series to draw definite
conclusions.
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